EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids

Ralph Mösges iD, Christoph Zeyen iD, Esther Raskopf iD, Cengizhan Acikel iD, Hacer Sahin iD, Silke Allekotte iD, Mandy Cuevas, Mohamed H Shamji iD, José Luis Subiza iD, Miguel Casanovas iD

Allergy · 2024

DOI: 10.1111/all.15910 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2024. Verfasst von Ralph Mösges und 9 weiteren Autor:innen. Beteiligte Einrichtung: ClinCompetence Cologne GmbH, Cologne, Germany. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Seasonal, Conjunctivitis, Conjunctivitis, Allergic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Inmunotek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is still great need to develop new strategies to improve the efficacy of allergen immunotherapies with optimal safety standards for patients. A new promising approach is to couple allergoids to mannan. The objective of this phase IIa/IIb study was to identify the optimal dose of mannan‐conjugated birch pollen allergoids for the short‐course treatment of birch pollen–induced allergic rhinoconjunctivitis.

Methods

For this prospective, randomized, double‐blind, placebo‐controlled, dose‐finding study, 246 birch pollen–allergic adults received 0.5 mL placebo or 1000, 3000 or 10,000 mTU/mL of mannan‐conjugated birch pollen allergoids at five pre‐seasonal visits. Efficacy was assessed by comparing allergic rhinoconjunctivitis symptoms and use of anti‐allergic medication during the peak of the birch pollen season 2020. Immunologic, tolerability and safety effects were also analysed.

Results

The highest dose of mannan‐conjugated birch pollen allergoids reduced the combined symptom and medication score during the peak birch pollen season by a median of 24.7% compared to placebo. The production of Bet v 1 specific IgG4 significantly increased in a dose‐dependent manner (3.6‐ and 4.5‐fold) in the 3000 and 10,000 mTU/mL groups. The Bet v 1 specific IgE/IgG4 ratio was also strongly reduced (up to −70%). No fatalities nor serious adverse events were reported, and no adrenaline was used. In total, four systemic reactions occurred (two grade I and two grade II).

Conclusion

All doses of mannan‐conjugated birch pollen allergoids can be considered as safe. Since the application of 10,000 mTU/mL resulted in the highest efficacy, this dose qualifies for further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, Allergic, SeasonalConjunctivitisConjunctivitis, AllergicAdultHumansAllergoidsAllergensPollenBetulaMannansProspective StudiesDesensitization, ImmunologicTreatment OutcomeDouble-Blind MethodImmunoglobulin G

Stichwörter der Autor:innen

allergic rhinoconjunctivitisallergoidbirch pollencombined symptom and medication scoremannan conjugate

Substanzen

AllergoidsAllergensMannansImmunoglobulin G

Autor:innen und Institutionen

  • ClinCompetence Cologne GmbH, Cologne, Germany.
  • Faculty of Medicine, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.
  • Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin,…
  • Carl Gustav Carus Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine (and University Hospital), Technische Universität Dresden, Dresden, Germany.
  • Allergy and Clinical Immunology Section, Imperial College London, London, UK.
  • Inmunotek S.L., Madrid, Spain.

ORCID-Profile: Ralph Mösges, Christoph Zeyen, Esther Raskopf, Cengizhan Acikel, Hacer Sahin, Silke Allekotte, Mohamed H Shamji, José Luis Subiza, Miguel Casanovas

Förderung

  • Inmunotek

Zitieren

APA

Mösges, R., Zeyen, C., Raskopf, E., Acikel, C., Sahin, H., Allekotte, S., Cuevas, M., Shamji, M. H., Subiza, J. L., & Casanovas, M. (2024). A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids. Allergy. https://doi.org/10.1111/all.15910

Vancouver

Mösges R, Zeyen C, Raskopf E, Acikel C, Sahin H, Allekotte S, et al. A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids. Allergy. 2024. doi:10.1111/all.15910

BibTeX
@article{Msges2024,
  author = {Mösges, Ralph and Zeyen, Christoph and Raskopf, Esther and Acikel, Cengizhan and Sahin, Hacer and Allekotte, Silke and Cuevas, Mandy and Shamji, Mohamed H and Subiza, José Luis and Casanovas, Miguel},
  title = {A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.15910}
}
Kostenlos starten →